0000200406 false 0000200406 2021-01-26 2021-01-26 0000200406 us-gaap:CommonStockMember 2021-01-26 2021-01-26 0000200406 jnj:A0.250NotesDue2022Member 2021-01-26 2021-01-26 0000200406 jnj:A0.650NotesDue2024Member 2021-01-26 2021-01-26 0000200406 jnj:A5.50NotesDue2024Member 2021-01-26 2021-01-26 0000200406 jnj:A1.150NotesDue2028Member 2021-01-26 2021-01-26 0000200406 jnj:A1.650NotesDue2035Member 2021-01-26 2021-01-26
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
January 26, 2021
Johnson & Johnson
(Exact name of registrant as specified in its charter)

New Jersey | 1-3215 | 22-1024240
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.)

One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number, including area code:
732-524-0400
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, Par Value $1.00 | JNJ | New York Stock Exchange
0.250% Notes Due January 2022 | JNJ22 | New York Stock Exchange
0.650% Notes Due May 2024 | JNJ24C | New York Stock Exchange
5.50% Notes Due November 2024 | JNJ24BP | New York Stock Exchange
1.150% Notes Due November 2028 | JNJ28 | New York Stock Exchange
1.650% Notes Due May 2035 | JNJ35 | New York Stock Exchange

Item 2.02 Results of Operations and Financial Condition
On January 26, 2021, Johnson & Johnson issued the attached press release announcing its sales and earnings for the fourth quarter and full year ended January 3, 2021.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.

Exhibit No. | Description of Exhibit
99.1 | Press Release dated January 26, 2021 for the period ended January 3, 2021
99.2 | Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings for the fourth quarter and full year
104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

|  | Johnson & Johnson |
|  |  | (Registrant) |
Date: | January 26, 2021 | By: | /s/ Robert J. Decker, Jr. |
|  |  | Robert J. Decker, Jr. Controller (Principal Accounting Officer) |